- Home
- LSCC vs EXEL Comparison
LSCC vs EXEL Comparison
Compare LSCC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSCC | EXEL |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 11.4B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LSCC | EXEL |
|---|---|---|
| Price | $148.87 | $52.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $103.75 | $46.50 |
| AVG Volume (30 Days) | 2.1M | ★ 2.2M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 0.16 | ★ 0.79 |
| Revenue | $385,961,000.00 | ★ $452,477,000.00 |
| Revenue This Year | $36.12 | $13.61 |
| Revenue Next Year | $19.98 | $13.13 |
| P/E Ratio | $903.31 | ★ $67.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $46.48 | $33.76 |
| 52 Week High | $155.82 | $53.93 |
Technical Indicators
Market Signals| Indicator | LSCC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 60.12 |
| Support Level | $65.99 | $40.17 |
| Resistance Level | $155.82 | N/A |
| Average True Range (ATR) | 8.36 | 1.55 |
| MACD | -1.10 | 0.02 |
| Stochastic Oscillator | 73.07 | 80.09 |
Price Performance
Historical ComparisonAbout LSCC Lattice Semiconductor Corporation
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.